NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023

Published:2023-07 Issue:7 Volume:21 Page:694-704
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Benson Al B.¹,D’Angelica Michael I.²,Abrams Thomas³,Abbott Daniel E.⁴,Ahmed Aijaz⁵,Anaya Daniel A.⁶,Anders Robert⁷,Are Chandrakanth⁸,Bachini Melinda⁹,Binder David¹⁰,Borad Mitesh¹¹,Bowlus Christopher¹²,Brown Daniel¹³,Burgoyne Adam¹⁴,Castellanos Jason¹⁵,Chahal Prabhleen¹⁶,Cloyd Jordan¹⁷,Covey Anne M.²,Glazer Evan S.¹⁸,Hawkins William G.¹⁹,Iyer Renuka²⁰,Jacob Rojymon²¹,Jennings Lawrence¹,Kelley R. Kate²²,Kim Robin²³,Levine Matthew²⁴,Palta Manisha²⁵,Park James O.²⁶,Raman Steven²⁷,Reddy Sanjay¹⁵,Ronnekleiv-Kelly Sean⁴,Sahai Vaibhav²⁸,Singh Gagandeep²⁹,Stein Stacey³⁰,Turk Anita³¹,Vauthey Jean-Nicolas³²,Venook Alan P.²²,Yopp Adam³³,McMillian Nicole³⁴,Schonfeld Ryan³⁴,Hochstetler Cindy³⁴

Affiliation:

1. Robert H. Lurie Comprehensive Cancer Center of Northwestern University

2. Memorial Sloan Kettering Cancer Center

3. Dana-Farber/Brigham and Women’s Cancer Center

4. University of Wisconsin Carbone Cancer Center

5. Stanford Cancer Institute

6. Moffitt Cancer Center

7. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

8. Fred & Pamela Buffett Cancer Center

9. The Cholangiocarcinoma Foundation

10. University of Colorado Cancer Center

11. Mayo Clinic Comprehensive Cancer Center

12. UC Davis Comprehensive Cancer Center

13. Vanderbilt-Ingram Cancer Center

14. UC San Diego Moores Cancer Center

15. Fox Chase Cancer Center

16. Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

17. The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

18. The University of Tennessee Health Science Center

19. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

20. Roswell Park Comprehensive Cancer Center

21. O’Neal Comprehensive Cancer Center at UAB

22. UCSF Helen Diller Family Comprehensive Cancer Center

23. Huntsman Cancer Institute at the University of Utah

24. Abramson Cancer Center at the University of Pennsylvania

25. Duke Cancer Institute

26. Fred Hutchinson Cancer Center

27. UCLA Jonsson Comprehensive Cancer Center

28. University of Michigan Rogel Cancer Center

29. City of Hope National Medical Center

30. Yale Cancer Center/Smilow Cancer Hospital

31. Indiana University Melvin and Bren Simon Comprehensive Cancer Center

32. The University of Texas MD Anderson Cancer Center

33. UT Southwestern Simmons Comprehensive Cancer Center

34. National Comprehensive Cancer Network

Abstract

In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.

Publisher

Harborside Press, LLC

Subject

Oncology

Reference39 articles.

1. Cancer statistics, 2023;Siegel RL,2023

2. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study;Park J,2009

3. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer;Oh DY,2022

4. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study;Yoo C,2021

5. Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial;Hyung J

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper;Critical Reviews in Oncology/Hematology;2024-02

2. New trends in diagnosis and management of gallbladder carcinoma;World Journal of Gastrointestinal Oncology;2024-01-15

3. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers;International Journal of Molecular Sciences;2024-01-15

4. Challenges in diagnosing and managing cystic duct carcinoma: A case report from Syria;International Journal of Surgery Case Reports;2024-01

5. Prognostic Impact of Neoadjuvant Chemotherapy in Localized or Locoregionally Advanced Gallbladder Cancer: a Population-Based and Propensity Score Matched SEER Analysis;2023-11-20